Atlanta, GA. – Celtaxsys, Inc., a clinical stage pharmaceutical company focused on developing anti-inflammatory therapies for cystic fibrosis (CF) lung disease and other rare, orphan conditions, announced today that Chief Executive Officer Greg Duncan will present a corporate overview at the Jefferies 2016 Healthcare Conference and the JMP Securities Life Sciences Conference in June.
Details of the two presentations are as follows:
Jefferies 2016 Healthcare Conference in New York, NY
Date: Friday, June 10
Presentation Time: 8:00 AM ET
Breakout Session: 8:30 AM ET
JMP Securities Life Sciences Conference in New York, NY
Date: Wednesday, June 22
Presentation Time: 3:30 PM ET
About Celtaxsys: Our flagship investigational medicine, oral once daily acebilustat, is aimed at preserving lung function in cystic fibrosis (CF) by specifically modulating key aspects of a dysregulated (i.e. over-activated) immune response. It is well known that an over-stimulated inflammatory response is the primary catalyst for the excessive morbidity and premature mortality associated with CF. We aim to investigate whether treatment with acebilustat, in conjunction with existing therapies, helps patients return to homeostasis, or a more “normalized” immune response. A more normalized immune response could lead to improved lung function and better quality of life for patients living with CF. Celtaxsys is headquartered in Atlanta, Georgia, USA, with a subsidiary office in Brisbane, Queensland, Australia.
Bill Reddick, Chief Financial Officer
+1 (470) 206-0153 ext. 103